Stakeholders ask for flexibility, more examples in FDA guidance on overall survival in cancer trials
Stakeholders asked the US Food and Drug Administration for more examples in comments on a recently issued guidance on the use of overall survival as an endpoint in oncology drug clinical trials. They ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results